Abstract
Objectives: Cell therapy using induced pluripotent stem cell (iPSC) technology receives enormous attention. We have developed a system for large-scale production of murine iPS cell derived cardiomyocytes (iPS-CM) and designed a strategy for co-transplantation of iPS-CM and mesenchymal stem cells (MSC) in order to improve intramyocardial cell retention and integration. Here, we specifically tested whether factors secreted from MSC improve the iPS-CM tolerance to ischemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
